Medicine has long studied female biology less thoroughly than male biology, and that gap now shows up in everything from diagnoses to the answers AI models give. Evvy is betting that a single at-home swab, repeated at scale, can generate the missing data and turn it into better care.

Evvy has closed a $40 million Series B round led by Catalio Capital Management. Founded by Priyanka Jain, Laine Bruzek and Pita Navarro, the company is known for an at-home test that uses metagenomic next-generation sequencing (mNGS) to map the vaginal microbiome from one swab. It describes the test as the only one of its kind to hold both CLIA and CLEP certification.

The process is simple for the user. She mails a sample to Evvy’s lab, where it is sequenced in-house. Clinicians registered on the platform then review the findings, which appear in the patient’s online portal along with a diagnosis, an explanation and suggested next steps, including tailored prescriptions where they make sense.

Testing and treatment are only the first layer of Evvy’s strategy. The larger goal is a connected dataset that links microbiome biology with symptoms, treatments and eventual outcomes. Each new test feeds that loop, which Jain believes can sharpen care over time and surface biomarkers nobody has identified yet. The company has already used its data to describe new subtypes of bacterial vaginosis.

Jain’s core argument is that precision medicine for women cannot be built on datasets that never properly measured female biology. She points to research showing that leading AI models often stumble on women’s health questions as evidence of the problem. In her view, AI only becomes useful here when it is fed new biological data at scale, so it can find links between hormones, microbes, symptoms, treatments and fertility outcomes that traditional research has missed.

Evvy’s research team is now building evidence connecting the vaginal microbiome to infertility, gynecological cancers, preterm birth, IVF success and repeated pregnancy loss. The hope is to replace vague labels such as “unexplained infertility” with answers grounded in data.

Longer term, Jain wants Evvy’s test to become something like a modern Pap smear: a non-invasive sample taken at home that gives women regular insight into infections, inflammation, fertility, PCOS, endometriosis, perimenopause and HPV progression. Evvy is not alone in the space, with JunoBio, TinyHealth and Daye also building in vaginal health, but its emphasis on research-grade data sets it apart.